📰 Nasdaq Bcli News
Page 2 - Nasdaq Bcli News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Bcli. Real-time updates on events, politics, business and more.
December 3, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) was the recipient of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 3,770,000 shares, a growth of 5.6% from the October 31st total of 3,570,000 shares. Based on an average daily volume of 2,320,000 […]
November 16, 2023
StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group cut Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research report on Thursday, September 28th. […]
November 15, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 3,570,000 shares, a decrease of 20.5% from the October 15th total of 4,490,000 shares. Approximately 9.8% of the company’s stock are short sold. Based on an average daily […]
October 22, 2023
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group cut Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research report on Thursday, […]
October 4, 2023
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock. Separately, Maxim Group downgraded Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 28th. […]
June 23, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.26 and traded as high as $2.40. Brainstorm Cell Therapeutics shares last traded at $2.32, with a volume of 301,181 shares changing […]
May 30, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 2,870,000 shares, a decline of 9.2% from the April 30th total of 3,160,000 shares. Approximately 9.5% of the company’s stock are short sold. […]
May 13, 2023
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday. Separately, Maxim Group increased their target price on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, […]
May 13, 2023
StockNews.com downgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a report issued on Friday morning. Separately, Maxim Group boosted their price target on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the company a buy rating in a report on Friday, March 31st. […]
May 4, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,930,000 shares, a decrease of 5.5% from the March 31st total of 3,100,000 shares. Currently, 10.4% of the company’s stock are sold short. Based on an […]